Active Biotech updates on the clinical phase Ib/IIa study in tasquinimod. https://lnkd.in/dcQhNh6u
Om oss
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
- Webbplats
-
http://www.activebiotech.com
Extern länk för Active Biotech AB
- Bransch
- Bioteknik
- Företagsstorlek
- 2–10 anställda
- Huvudkontor
- Lund, SE
- Typ
- Publikt aktiebolag
- Grundat
- 1998
Adresser
-
Primär
Få vägbeskrivning
Scheelevägen 22
Lund, SE 22363, SE
-
Få vägbeskrivning
Anställda på Active Biotech AB
Uppdateringar
-
Active Biotech enters agreement for a clinical study of tasquinimod in myelofibrosis https://lnkd.in/dSBxNBGz
Active Biotech enters agreement for a clinical study of tasquinimod in myelofibrosis
https://www.activebiotech.com
-
Clinical activity and safety of naptumomab and docetaxel to be presented at ASCO 2024 https://lnkd.in/dkt99aEQ
Clinical activity and safety of naptumomab and docetaxel to be presented at ASCO 2024
https://www.activebiotech.com
-
We have entered into an exclusive license agreement with the Wistar Institute of Anatomy and Biology (“Wistar”), Philadelphia, US for the global rights to Wistars interest in the joint IP relating to the use of tasquinimod in combination therapy for multiple myeloma, for further development and commercialization. https://lnkd.in/dSJduaQe
Active Biotech förvärvar exklusiva rättigheter till patent på tasquinimod i kombinationsterapi
https://www.activebiotech.com
-
Analysguiden av Aktiespararna (in Swedish) New analysis of Active Biotech: “Planering för kommande studier”
Active Biotech: Planering för kommande studier | Aktiespararna
aktiespararna.se
-
Interview with Prof. Dr. Axel Glasmacher about the potential of tasquinimod in myelofibrosis
Interview with Prof. Dr. Axel Glasmacher, Independent Board Member at Active Biotech
https://www.activebiotech.com
-
Active Biotech Interim Report Q1 2024 is now available on Active Biotech's website. https://lnkd.in/dgFuPAnB
-
-
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops The clinical phase I biodistribution study Safety, Tolerability, and Distribution of Laquinimod Eye Drops: The LION Study (clinicaltrials.gov NCT06161415) with laquinimod eye drops is now recruiting patients following the approval from the Food and Drug Administration (FDA) and the Institutional Review Board at Stanford University School of Medicine. Read the press release here: https://lnkd.in/gBPprT_2
-
-
Active Biotech today announced an update to the timelines of its scheduled clinical studies to be initiated in 2024, backed by the company’s recently completed successful financing round. Read the press release here: https://lnkd.in/dPvgAFU4
-
-
Positive preclinical tasquinimod data presented at ASH 2023 is now available on Active Biotech’s website Read the presentations here: https://lnkd.in/dMacDNsv and the press release here: https://lnkd.in/dnNuPsZp
-